Ecstatic to see these rapid relevant @iCardioAlliance HF guidelines come to open access publication!! >50% of writing task force is outside of Europe and North America with cascading guidelines based on availability + accessibility. Global experts + thought leaders bring a

New @JACCJournals #JACCHF position statement: everything you want to know re: ischemic heart disease in pts w #HF 🔹Which meds & when 🔹Role of ischemia & viability testing 🔹Patient selection & timing for revasc 🔹Areas for further research https://t.co/y3pgcCN1Ix

Sleigh the season with the most personal gift around. Get them a Cameo video!

Distinct residual #congestion phenotypes carry different risks, From #PROTECT & #RELAX_AHF_2: 📍37% of #ADHF patients remain #congested at discharge 📍Intravascular residual congestion: best diuretic response, but still ⬆️mortality☠️ compared to decongested patients

Thank you @MedWomenIntl @FMWCanada @AMWADoctors for this opportunity & electing me as your Executive Vice President of North America

Top3 heart failure trials in November 2025 🥇Redefining HF subtypes according to skeletal muscle mass @NatureMedicine 🥈Urinary markers in HF @ESC_Journals @MartaCoboMarcos 🥉Worsening vs advanced HF @escardio

#Levosimendan to Facilitate Weaning From #ECMO in Patients With Severe Cardiogenic Shock : #LEVOECMO Trial 📌RCT in VA-ECMO cardiogenic shock (N=205): Levosimendan vs placebo. 📌ECMO weaning at 30d: 68.3% vs 68.3% (P=0.92) — no benefit. 📌No differences in ECMO duration, ICU

#UpdatesinHF2025 is where evidence meets action. With only 6 in-person seats left, join global leaders in heart failure to focus on high-impact, guideline-driven care across all HF syndromes. Radisson Blu Waterfront, Stockholm | 15–16 December 2025 | EACCME-Accredited Free

🔍 Poor adherence to GDMT remains a major barrier to improving outcomes in heart failure. A new HFA/ESC scientific statement provides insights and solutions. https://t.co/vABmIkaxKo @EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd #EJHF

📣Our paper is out in @ehj_ed @ESC_Journals on Risk factors for #cardiovasculardisease in women 🫀Our review of sex-specific & traditional CVD risk & risk-enhancing factors in women identifies areas of knowledge gaps to consider for investigation 🫀 This review is a call to

Grateful to share that I’ve been promoted to Professor of Medicine @IcahnMountSinai @MountSinaiHeart Titles are milestones — and their real meaning lies in people, purpose, and continued growth. For me, this “milestone” reflects the sacred privilege of caring for patients,

Lots of confusion about menopausal hormone therapy right now —who should get it, when to start, and what is the🫀 risk? Our new review led by @BrighamMedRes Ruby Guo covers timing, route, and CV risk stratification for midlife women. 🔗: https://t.co/XCHqVM9tqx

Full paper available here 👇 🔗 https://t.co/bipLYJOCma access. Figures & supplementary data included.#HeartFailure #Workforce #Cardiology

🚨 New paper alert! Canada’s growing HF workforce crisis — national analysis of gaps & solutions🩺🇨🇦 Published @JCardFail. @JustinEzekowitz @ShelleyZieroth @anulall @MargotDavisMD @robmentz @FilioBillia @CanHFSociety @MarcoMetra @jozinetm @CMA_Docs @Royal_College #HF #Workforce

Turn your ideas into impact at #HeartFailure26 & be part of the global #HeartFailure community 📍Barcelona & Online | 9-12 May 2026 📍Abstract deadline: 8 January 📝 📍Clinical case deadline: 20 January 🩺 Join us in May: 🔗 https://t.co/vPqFmhylIC @escardio #HFA_ESC #HFAyoung

ICYMI: Register for our upcoming CardioAbstracts: HF + Kidney Link on 12/3! Featuring abstracts from the FINEARTS-HF trial and expert HFSA faculty: @JavedButler1 @CardioSM @ShelleyZieroth @JawadHButt @Kieranfdocherty Save your spot >>

A joy to work with leading co-authors to develop this compendium; it’s what we all need to know RE: prevention #CVD in one location. Shout out - Leandro Slipczuk @AJPCardio

⚠️Pharmacological treatment for 👥 with #obesity and #HeartFailure: Focus on glucagon-like peptide-1 receptor agonists #EHJHF expert consensus 📝 #GLP1A #aGLP1 #HF #adiposity

🎙️New #HFACardioTalk Episode! In this episode, Dr #FelixLindberg, Mrs #MarthaKyriakou, & @m4ggiesimpson explore why the complexity of #heartfailure & multimorbidity makes true multidisciplinary, team-based care essential Find out about: 📍Key professional roles within the HF

🗞️ Pharmacological treatment for patients with #obesity and #HeartFailure: Focus on #GLP_1 receptor agonists. #EuropeanJournalofHeartFailure expert consensus document @escardio @ESC_Journals @GiuseppeGalati_ @AmrAbdin10 @HanCardiomd https://t.co/pcPiEyJQZF

Are GLP-1s the first longevity drugs? There is no cure for mortality, but much can be done to make our lives longer in health and happiness #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @ShelleyZieroth @hvanspall @DrMarthaGulati @CMichaelGibson @AndrewJSauer

Guideline-directed medical therapy after revascularization and outcomes in ischaemic cardiomyopathy see: https://t.co/K5gQHJxQwT @EJHFEiC @JanBiegus @Ppponikowski #HFA_ESC @hvanspall @ShelleyZieroth @FudimMarat @gcfmd @AlexMebazaa @MarcoMetra @GianluSava @thiele_holger